- Zimmer Biomet has greatly underperformed the S&P 500 as well as the iShares IHI, been stagnant over the past 5 years.
- The street consensus gives some hope for the projected growth with an estimated 28.67% FCF and 7.19% EBIT CAGR over the next 5 years.
- Zimmer Biomet carries noteworthy risks and faces significant challenges while its peers perform much better with an advantageous risk-reward profile.
- Based on my valuation model, the stock is fairly priced with a slightly higher price target at $139.
For further details see:
Zimmer Biomet Is Hobbling Behind The Market